Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06431815 · ClinicalTrials.gov registry record
ADVENT Post Approval Study
A clinical trial of Paroxysmal Atrial Fibrillation, sponsored by Boston Scientific Corporation.
- Active
- Registry status
- 228
- Enrollment target
- 20
- Study locations
NCT06431815: Active study of Paroxysmal Atrial Fibrillation, sponsored by Boston Scientific Corporation.
NCT06431815 is a study of Paroxysmal Atrial Fibrillation that is active but no longer recruiting, run by Boston Scientific Corporation. The registered enrollment target is 228 participants, below the 850-participant average among 24 other Paroxysmal Atrial Fibrillation trials with a reported enrollment target (73% lower). The trial reports 20 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06431815, a study of Paroxysmal Atrial Fibrillation, is active but no longer recruiting, sponsored by Boston Scientific Corporation.
- ACTIVE NOT RECRUITING
- Registry status
- 228 participants
- Enrollment target
- 20
- Study locations
Study Summary
The ADVENT Post Approval Study (PAS) is a prospective, global, multicenter, observational study.
Primary Outcome
* Early Onset: Acute primary safety endpoint events, events occurring up to 7 days post-Index Procedure or hospital discharge, whichever is later including serious procedure-related and device-related adverse events. * Death * Myocardial infarction (MI) * Persistent phrenic nerve palsy * Stroke/Cerebrovascular accident (CVA) * Transient ischemic attack (TIA) * Peripheral or organ thromboembolism * Cardiac tamponade / perforation * Pericarditis * Pulmonary edema * Serious vas
Conditions Studied
Interventions
- DEVICE FARAPULSE™ Pulsed Field Ablation System
Study Locations (20)
Florida
- Florida Heart Rhythm Specialists, PLLC - Fort Lauderdale
- Baptist Medical Center - Jacksonville
- Mount Sinai Medical Center - Miami Beach
- Tallahassee Memorial Hospital - Tallahassee
- AdventHealth Tampa - Tampa
New York
- New York Hospital Queens - Flushing
- Columbia University Medical Center - New York
- Northwell Health - New York
- Montefiore Medical Center - The Bronx
Alabama
- Mobile Infirmary Medical Center - Mobile
Arizona
- Scottsdale Healthcare - Shea - Scottsdale
California
- Alta Bates Summit Medical Center - Oakland
District of Columbia
- Washington Hospital Center - Washington D.C.
Georgia
- Memorial Health University Medical Center - Savannah
Louisiana
- Ochsner Clinic Foundation - New Orleans
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 228 participants |
| Start Date | 2024-09-25 |
| Est. Completion | 2029-10 |
What the registry record for NCT06431815 still lists
NCT06431815 is an observational study that tracks outcomes without assigning an intervention. The registered 228 participants enrollment target is mid-sized for trials with a published cap, below the 850-participant average among 24 other Paroxysmal Atrial Fibrillation trials with a reported enrollment target (73% lower).
The record links to 1 condition, with Paroxysmal Atrial Fibrillation appearing as the primary indexed condition, and to 1 intervention - of which FARAPULSE™ Pulsed Field Ablation System is the first listed.
NCT06431815 names 20 study sites across 13 states, led by Florida, New York, Alabama.
Frequently Asked Questions
What is clinical trial NCT06431815 about?
NCT06431815 is a clinical study titled "ADVENT Post Approval Study". The ADVENT Post Approval Study (PAS) is a prospective, global, multicenter, observational study.
What is the current status of trial NCT06431815?
This trial is currently active not recruiting. The enrollment target is 228 participants. The study started on 2024-09-25. Estimated completion is 2029-10.
What conditions does trial NCT06431815 study?
This clinical trial studies the following conditions: Paroxysmal Atrial Fibrillation.
What interventions are being tested in trial NCT06431815?
The interventions under investigation include: FARAPULSE™ Pulsed Field Ablation System (DEVICE).
Who is sponsoring clinical trial NCT06431815?
This trial is sponsored by Boston Scientific Corporation, which has 280 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06431815 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, District of Columbia, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Paroxysmal Atrial Fibrillation
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06431815's enrollment target sits among peer trials
228 13th of 24 higher than 12 of 24 other Paroxysmal Atrial Fibrillation trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Paroxysmal Atrial Fibrillation trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
ULTRA-HFIB-Redo: Ultrasound-based Renal Sympathetic Denervation vs Control in Redo Ablation Patients
RECRUITING · NA
-
Determinates of Atrial Tracking and Prevalence of Atrial Fibrillation in the Micra AV2 (DANCE AFIB)
RECRUITING
-
STOP AF First Post-Approval Study
RECRUITING
-
The Long-term Safety and Effectiveness Evaluation of the QDOT MICRO System Use in Conjunction With VISITAG SURPOINT Module for the Treatment of Symptomatic Drug Refractory Paroxysmal Atrial Fibrillation.
RECRUITING
-
EXercise Cardiac Magnetic Resonance Assessment of Left Atrial Mechanics Following Ablation
RECRUITING
-
Biomarker-Guided Optimization of Transcutaneous Vagal Stimulation for Atrial (BiG tVNS-AF)
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05107908 · 228 participants · NA
Neuronal and Behavioral Effects of an Implicit Priming Approach to Improve Eating Behaviors in Obesity
- NCT05547698 · 228 participants · NA
A Study of Venoarterial ECMO vs Off-Pump Bilateral Orthotopic Lung Transplantation
- NCT05630963 · 228 participants
Beyond Monoamines: The Role of the Nociceptin/Orphanin FQ Receptor in Major Depression
- NCT06073665 · 228 participants · Phase 4
Dosing of LT4 in Older Individuals
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI